Cite

HARVARD Citation

    Azaro, A. et al. (n.d.). 301 First-in-human phase I dose-escalation study of a MET/AXL/FGFR inhibitor, S 49076, in patients with advanced solid tumors. European journal of cancer. pp. S54-. [Online]. 
  
Back to record